Calendar

CarMax's prior quarter beat EPS and revenue, but recent reporting highlights used-auto-market softness and job reductions; current consensus revisions and the required pre-event tape evidence were not verified.

Uranium Energy's checked previous-quarter figures missed both EPS and revenue expectations; although current estimates were visible, no positive revisions, tape confirmation, or complete risk assessment supported an upside-surprise setup.

Conagra's checked sources did not establish current EPS/revenue consensus or pre-event tape; recent discussion of a dividend reduction and a large goodwill impairment concern also warrants caution pending primary-source verification.

Jabil has favorable analyst-revision evidence, raised FY2026 guidance, and exposure to cloud/data infrastructure demand; the cited current-quarter consensus is credible. However, a pre-event price/volume tape test and the required close-location signal could not be established from the checked sources, so the score remains below the investable threshold.

FactSet has a recent history of beating EPS and revenue consensus, but the checked sources supplied inconsistent EPS expectations and no positive revisions or tape confirmation; the setup is incomplete.

Cal-Maine's most recent reported quarter swung to a loss and missed EPS estimates; current revenue consensus and revision data were not verified, and no pre-event tape evidence supports a contrarian surprise thesis.

Micron has positive near-term EPS estimate revision evidence and substantial HBM/AI demand momentum, but its own $50B revenue guidance midpoint is below the cited $50.86B consensus; the recent tape is mixed and does not show a qualifying >1.5x volume session. The evidence therefore supports a partial setup, not a qualifying pre-earnings candidate.

The checked search did not surface credible current-quarter EPS and revenue consensus together, revision evidence, or qualifying tape; this is an unqualified calendar entry rather than an actionable surprise setup.

Accenture has marginally positive EPS estimate revision evidence and a credible consensus for the coming quarter, but the checked revenue estimate and recent business commentary do not demonstrate upside against expectations. Price/volume qualification and sector-relative strength were also not established, leaving this as a thin-data non-qualifier.

Acuity consensus sources indicate expected EPS growth and a $1.25B revenue outlook estimate, but no positive revisions or recent tape/volume confirmation were verified; available analyst coverage is limited.

Aehr's current consensus implies strong sequential and year-over-year revenue growth and recent reported EPS beat, but the latest quarter missed revenue expectations and no estimate revision, qualifying tape, or customer-concentration risk assessment was verified.